Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption
BA Singer, J Feng, H Chiong-Rivero - Journal of Neurology, 2024 - Springer
Multiple sclerosis (MS) is characterized by progressive neuroinflammation and
neurodegeneration from disease onset that, if left untreated, can result in the accumulation …
neurodegeneration from disease onset that, if left untreated, can result in the accumulation …
COVID-19 and multiple sclerosis: challenges and lessons for patient care
L Prosperini, G Arrambide, EG Celius… - The Lancet Regional …, 2024 - thelancet.com
During the COVID-19 pandemic, people with multiple sclerosis (MS) and their healthcare
providers have faced unique challenges related to the interaction between SARS-CoV-2 …
providers have faced unique challenges related to the interaction between SARS-CoV-2 …
Association between anti-CD20 therapies and COVID-19 severity among patients with relapsing-remitting and progressive multiple sclerosis
E Januel, D Hajage, P Labauge, E Maillart… - JAMA Network …, 2023 - jamanetwork.com
Importance In patients with multiple sclerosis (MS), factors associated with severe COVID-19
include anti-CD20 therapies and neurologic disability, but it is still unclear whether these 2 …
include anti-CD20 therapies and neurologic disability, but it is still unclear whether these 2 …
Association of multiple‐sclerosis‐related mortality with COVID‐19 and other common infections: a multiple causes of death analysis
U Fedeli, C Barbiellini Amidei, F Avossa… - European Journal of …, 2023 - Wiley Online Library
Background and purpose People with multiple sclerosis (MS) suffer from higher infection‐
related mortality compared to the general population; however, sparse data are available on …
related mortality compared to the general population; however, sparse data are available on …
The impact of hybrid immunity on immune responses after SARS‐CoV‐2 vaccination in persons with multiple sclerosis treated with disease‐modifying therapies
M Rabenstein, OG Thomas, G Carlin… - European Journal of …, 2023 - Wiley Online Library
Background and purpose Hybrid immunity to severe acute respiratory syndrome coronavirus
2 (SARS‐CoV‐2) develops from a combination of natural infection and vaccine‐generated …
2 (SARS‐CoV‐2) develops from a combination of natural infection and vaccine‐generated …
Exploring the working life of people with multiple sclerosis during the COVID-19 pandemic in Sweden
Background The COVID-19 pandemic led to vast changes in working life and conditions in
which we work. These changes may affect people with multiple sclerosis (PwMS) differently …
which we work. These changes may affect people with multiple sclerosis (PwMS) differently …
Sars-CoV2 infection in pregnant women with multiple sclerosis
MG Aprea, I Schiavetti, E Portaccio… - Multiple Sclerosis …, 2023 - journals.sagepub.com
Background: In the general population, maternal SARS-CoV-2 infection during pregnancy is
associated with worse maternal outcomes; however, only one study so far has evaluated …
associated with worse maternal outcomes; however, only one study so far has evaluated …
Multiple Sclerosis and COVID-19: An Overview on Risk, Severity, and Association With Disease Modifying Therapies
M Hollist, A Hollist, K Au, C Betts… - Neuroscience …, 2024 - journals.sagepub.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus,
emerged in December 2019, sparking a global health crisis. While initially recognized as a …
emerged in December 2019, sparking a global health crisis. While initially recognized as a …
[HTML][HTML] Electronic health record data for assessing risk of hospitalization for COVID-19: Methodological considerations applied to multiple sclerosis
Introduction During the COVID-19 pandemic, electronic health record (EHR) data has been
used to investigate disease severity and risk factors for severe COVID-19 in people with …
used to investigate disease severity and risk factors for severe COVID-19 in people with …
Coronavirus disease 2019 infection among working-aged people with multiple sclerosis and the impact of disease-modifying therapies
C Murley, E Pettersson, J Hillert… - Multiple Sclerosis …, 2024 - journals.sagepub.com
Background The risk of coronavirus disease 2019 among people with multiple sclerosis with
different disease-modifying therapies is not well established. Objective To investigate the …
different disease-modifying therapies is not well established. Objective To investigate the …